JPMorgan recently raised its projections for weight loss drugs, expecting the drug category known as GLP-1 agonists to bring over $100B in annual sales by 2030 in a duopoly controlled by Novo Nordisk (NVO) (OTCPK:NONOF) and Eli Lilly (NYSE:LLY).
In a research note last week, JPMorgan analyst Chris Schott said that he did not rule out further sales upside for GLP-1s in obesity and diabetes, where the uptake of the drug class is fast rising amid social media hype.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased